Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.58 |
| ▸ | TSPO | P30536 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29862492 | 0.91 | HTR6 (0.47) | HTR6TSPOCA1CA2 | |
| SCHEMBL11828582 | 0.90 | HTR6 (0.60) | HTR6TSPOCA1CA2 | |
| SCHEMBL6699402 | 0.85 | HTR6 (0.71) | HTR6 | |
| SCHEMBL11823611 | 0.85 | HTR6 (0.55) | HTR6TSPOCA1CA2 | |
| SCHEMBL11822650 | 0.85 | HTR6 (0.67) | HTR6TSPO | |
| SCHEMBL11823623 | 0.85 | HTR6 (0.55) | HTR6TSPOCA1CA2 | |
| SCHEMBL6691719 | 0.84 | PLA2G2A (0.49) | HTR6TSPO | |
| SCHEMBL11827808 | 0.84 | HTR6 (0.54) | HTR6TSPOCA1CA2 | |
| SCHEMBL6982832 | 0.83 | HTR6 (0.46) | HTR6TSPO | |
| SCHEMBL6982837 | 0.83 | HTR6 (0.46) | HTR6TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | OPHIREX, INC (US) | 2025-04-15 | — | — | US | disclosed |
| CN-115379836-A | Early management and prevention of sepsis and sepsis-like syndrome | 奥菲瑞克斯公司 | 2022-11-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | PLA2R1, PLA2G12A, ACHE | HTR6 844/4885TSPO 3208/4885CA1 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.